Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
7,938,059
-
Number of holders
-
59
-
Total 13F shares, excl. options
-
16,126,888
-
Shares change
-
+5,649,108
-
Total reported value, excl. options
-
$138,720,293
-
Value change
-
+$48,924,159
-
Number of buys
-
30
-
Number of sells
-
-19
-
Price
-
$8.61
Significant Holders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) as of Q1 2021
64 filings reported holding XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share as of Q1 2021.
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) has 59 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16,126,888 shares
.
Largest 10 shareholders include Ikarian Capital, LLC (2,614,988 shares), Bain Capital Life Sciences Investors, LLC (2,119,540 shares), ORBIMED ADVISORS LLC (1,373,849 shares), BlackRock Inc. (1,091,753 shares), BVF INC/IL (1,091,579 shares), Sio Capital Management, LLC (804,597 shares), DRIEHAUS CAPITAL MANAGEMENT LLC (795,312 shares), VANGUARD GROUP INC (736,602 shares), Monashee Investment Management LLC (574,712 shares), and AXA S.A. (568,847 shares).
This table shows the top 59 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.